Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-May-23 4:17 PM View:  | Sapir Alex Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 3,750 | -- | -- | 100% 0 to 3.75K | |
| 19-May-23 4:18 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 3,750 | -- | -- | < 1% 3.58M to 3.58M | |
| 19-May-23 4:17 PM View: | Harrigan Edmund Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 3,750 | -- | -- | 62% 6.0K to 9.75K | |
| 19-May-23 4:15 PM View: | Hutson Nancy J Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 3,750 | -- | -- | 10% 37.76K to 41.51K | |
| 19-May-23 4:18 PM View: | Humphries William D. Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 2,538 | -- | -- | 100% 0 to 2.54K | |
| 19-May-23 4:16 PM View: | Loewy Caroline M Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-May-23 | Option Exercise | 3,750 | -- | -- | 100% 0 to 3.75K | |
| 26-Oct-22 4:41 PM View: | New Enterprise Associates 1... 10% Owner | Phasebio Pharmaceuticals Inc (PHAS) | 25-Oct-22 | Sale | 1,784,110 | $0.15 | $262,264.00 | (27%) 6.64M to 4.86M | |
| 24-May-22 5:14 PM View: | Burkhardt Glen SVP of Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 23-May-22 | Sale (Planned) | 11,248 | $0.79 | $8,885.92 | (100%) 11.25K to 0 | |
| 24-May-22 5:14 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 10,918 | $0.68 | $7,438.43 | 6% 172.78K to 183.7K | |
| 24-May-22 5:14 PM View: | Burkhardt Glen SVP of Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 11,248 | $0.68 | $7,663.26 | 100% 0 to 11.25K | |
| 24-May-22 5:15 PM View: | Arnold Susan Elizabeth SVP, Technical Operations | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 10,917 | $0.68 | $7,437.75 | 36% 30.32K to 41.24K | |
| 24-May-22 5:12 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 6,026 | $0.68 | $4,105.51 | 10% 59.74K to 65.77K | |
| 24-May-22 5:13 PM View: | Birchall Jonathan Chief Commercial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 20,000 | $0.68 | $13,626.00 | 100% 0 to 20.0K | |
| 24-May-22 5:13 PM View: | Hanson Kristopher SVP and General Counsel | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-22 | Grant | 4,831 | $0.68 | $3,291.36 | 133% 3.63K to 8.46K | |
| 23-Nov-21 6:55 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Grant | 5,623 | $2.01 | $11,302.20 | 3% 166.85K to 172.47K | |
| 23-Nov-21 6:54 PM View: | Arnold Susan Elizabeth SVP, Technical Operations | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Grant | 2,559 | $2.01 | $5,143.59 | 9% 27.76K to 30.32K | |
| 23-Nov-21 6:50 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Grant | 5,766 | $2.01 | $11,589.70 | 100% 0 to 5.77K | |
| 23-Nov-21 6:50 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Market Sale (Planned) | 5,766 | $2.37 | $13,665.40 | (100%) 5.77K to 0 | |
| 23-Nov-21 6:53 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Grant | 2,017 | $2.01 | $4,054.17 | 3% 57.72K to 59.74K | |
| 23-Nov-21 6:51 PM View: | Hanson Kristopher VP, Head of Legal | Phasebio Pharmaceuticals Inc (PHAS) | 19-Nov-21 | Grant | 1,545 | $2.01 | $3,105.45 | 74% 2.09K to 3.63K | |
| 08-Nov-21 6:26 PM View: | Hutson Nancy J Director | Phasebio Pharmaceuticals Inc (PHAS) | 08-Nov-21 | Option Exercise | 7,400 | $3.15 | $23,310.00 | 28% 26.36K to 33.76K | |
| 08-Nov-21 6:26 PM View: | Hutson Nancy J Director | Phasebio Pharmaceuticals Inc (PHAS) | 05-Nov-21 | Option Exercise | 26,360 | $2.31 | $60,908.60 | 100% 0 to 26.36K | |
| 03-Nov-21 7:30 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 03-Nov-21 | Option Exercise | 7,500 | $1.68 | $12,600.00 | 15% 50.22K to 57.72K | |
| 03-Nov-21 7:30 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 03-Nov-21 | Option Exercise | 20,000 | $1.24 | $24,800.00 | 14% 146.85K to 166.85K | |
| 30-Aug-21 5:52 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 27-Aug-21 | Option Exercise | 20,000 | $1.24 | $24,800.00 | 16% 126.85K to 146.85K | |
| 19-Aug-21 4:24 PM View: | Hutson Nancy J Director | Phasebio Pharmaceuticals Inc (PHAS) | 18-Aug-21 | Market Purchase | 3,000 | $3.08 | $9,240.00 | 300% 1.0K to 4.0K | (2%) |
| 18-Aug-21 10:00 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 18-Aug-21 | Market Purchase | 10,000 | $3.00 | $30,000.00 | 44% 22.94K to 32.94K | 7% |
| 04-Aug-21 6:58 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 03-Aug-21 | Grant | 7,500 | $1.68 | $12,600.00 | 18% 42.72K to 50.22K | |
| 14-Jul-21 7:06 PM View: | Arnold Susan Elizabeth VP, Preclinical and Chem | Phasebio Pharmaceuticals Inc (PHAS) | 12-Jul-21 | Grant | 4,519 | $1.74 | $7,863.06 | 19% 23.24K to 27.76K | |
| 24-May-21 6:11 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 1,419 | $2.80 | $3,973.20 | 3% 41.3K to 42.72K | |
| 24-May-21 6:09 PM View: | Hanson Kristopher VP, Head of Legal | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 1,088 | $2.80 | $3,046.40 | 109% 1.0K to 2.09K | |
| 24-May-21 6:10 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 3,964 | $2.80 | $11,099.20 | 3% 122.89K to 126.85K | |
| 24-May-21 6:09 PM View: | Arnold Susan Elizabeth VP, Preclinical and Chem | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 5,257 | $2.80 | $14,719.60 | 29% 17.98K to 23.24K | |
| 24-May-21 6:10 PM View: | York Michael VP, Corporate Development | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 2,897 | $2.80 | $8,111.60 | 70% 4.16K to 7.06K | |
| 24-May-21 6:11 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Grant | 3,811 | $2.80 | $10,670.80 | 100% 0 to 3.81K | |
| 24-May-21 6:11 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 20-May-21 | Market Sale | 3,811 | $3.29 | $12,538.20 | (100%) 3.81K to 0 | |
| 04-Dec-20 3:53 PM View: | Harrigan Edmund Director | Phasebio Pharmaceuticals Inc (PHAS) | 03-Dec-20 | Market Purchase | 6,000 | $4.12 | $24,720.00 | 100% 0 to 6.0K | (13%) |
| 24-Nov-20 4:04 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 24-Nov-20 | Market Purchase | 2,000 | $3.50 | $7,000.00 | 10% 20.94K to 22.94K | 3% |
| 24-Nov-20 4:04 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 23-Nov-20 | Market Purchase | 3,000 | $3.67 | $11,010.00 | 17% 17.94K to 20.94K | (2%) |
| 23-Nov-20 6:27 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 23-Nov-20 | Market Sale | 3,497 | $3.45 | $12,064.70 | (100%) 3.5K to 0 | (4%) |
| 23-Nov-20 6:42 PM View: | Hanson Kristopher VP, Head of Legal | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 999 | $3.00 | $2,997.00 | 100% 0 to 1.0K | |
| 23-Nov-20 6:34 PM View: | Mow Jonathan P Chief Executive Officer Director | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 3,643 | $3.00 | $10,929.00 | 3% 119.24K to 122.89K | |
| 23-Nov-20 6:36 PM View: | Arnold Susan Elizabeth VP, Preclinical and Chem | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 4,832 | $3.00 | $14,496.00 | 37% 13.15K to 17.98K | |
| 23-Nov-20 6:40 PM View: | York Michael VP, Corporate Development | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 2,662 | $3.00 | $7,986.00 | 177% 1.5K to 4.16K | |
| 23-Nov-20 6:27 PM View: | Burkhardt Glen VP, Human Resources | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 3,497 | $3.00 | $10,491.00 | 100% 0 to 3.5K | |
| 23-Nov-20 6:38 PM View: | Ballance David James VP, Research and Sci. Affairs | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 919 | $3.00 | $2,757.00 | 12% 7.6K to 8.52K | |
| 23-Nov-20 6:43 PM View: | Sharp John P Chief Financial Officer | Phasebio Pharmaceuticals Inc (PHAS) | 20-Nov-20 | Grant | 1,305 | $3.00 | $3,915.00 | 3% 40.0K to 41.3K | |
| 18-Nov-20 7:19 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 16-Nov-20 | Acquisition (other) | 2,144 | -- | -- | < 1% 2.47M to 2.47M | |
| 18-Nov-20 7:19 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 16-Nov-20 | Acquisition (other) | 10,586 | -- | -- | < 1% 2.47M to 2.48M | |
| 18-Nov-20 7:19 PM View: | Thorp Clay Director | Phasebio Pharmaceuticals Inc (PHAS) | 16-Nov-20 | Disposition (other) | 52,397 | -- | -- | (2%) 2.48M to 2.43M |
